liverdose.com

What It Is

LiverDose is an AI application focused on liver dosimetry, primarily for TARE dosimetry scenarios. According to the information on its page, it uses AI-powered timesaving tools to improve the segmentation process and combines them with evidence based prediction models to support dosimetry-guided treatment. Its core positioning is not as a general-purpose medical imaging AI tool, but as a solution for precise dose assessment in liver interventional therapy.

Core Capabilities

Based on the disclosed information, LiverDose appears to focus on two main capabilities. The first is AI-assisted segmentation, intended to reduce manual processing time in the dosimetry workflow. The second is prediction models based on evidence-based methods, helping clinicians make more informed treatment decisions in TARE dosimetry. The product emphasizes that “every patient is unique,” aiming to move from one-size-fits-all population-level dosing toward personalized assessments. Typical users include clinicians, clinical trial teams, and preclinical researchers.

Pricing and Integration

The crawled text does not disclose any free tier, trial options, licensing model, or specific pricing. It also does not state whether LiverDose supports hospital systems, imaging archive systems, radiotherapy/nuclear medicine workstations, or API integration. As a result, it is currently difficult to assess procurement cost, deployment complexity, or IT integration capabilities. Payment methods are not specified either.

Pros and Cons

Its strengths are a clearly defined vertical use case: it focuses on TARE liver dosimetry and addresses real pain points around segmentation, prediction, and workflow efficiency. If its models are indeed backed by clinical trial data, it could offer strong value for precision medicine and clinical research. The limitations are also fairly clear: the publicly available text does not provide key information such as model performance, validation data, regulatory certification, privacy compliance, or human review mechanisms. For a medical AI product, these factors directly affect trustworthiness and practical deployability.

Who It’s For and Access from China

This tool is better suited to professional institutions involved in TARE treatment, liver dosimetry research, clinical trials, or preclinical research, rather than ordinary patients or routine use by general radiology departments. Access from China is unknown, and the page does not mention a Chinese interface, local deployment, cross-border data handling, or support for domestic payment methods. If used in China, it is advisable to verify network accessibility, medical data compliance, hospital system integration, and whether local alternatives are available.